Children with cancer at no greater risk of severe Covid-19 infection, research shows
Posted on 10 December 2020
Data was collected on all children with cancer in the UK who on admission to hospital tested positive for Covid-19
Researchers – including academics from the University of York - analysed the severity of Covid-19 infection in children with cancer.
The results from the UK Paediatric Coronavirus Cancer Monitoring project - set up in April - found that the majority of patients either had mild infections or were asymptomatic. No patients died from Covid-19 and only five per cent required intensive care support.
Knowledge
The research was designed in cooperation with the Children’s Cancer and Leukaemia Group (CCLG) and the project enabled all centres in the UK that look after children with cancer to enrol into the study, which included Leeds Children's Hospital.
Dr Bob Phillips from the Centre for Reviews and Dissemination said: “Being involved with the study allowed the clinical team to be at the cutting edge of knowledge about how the SARS-CoV2 virus was affecting children and young people being treated for cancer. We could immediately use this knowledge to send clear messages to our patients and the families at Leeds Children's Hospital and nationally via a well established network of children's cancer doctors.
“This supported giving clear, increasingly reassuring messages, and encouragement to carry on giving children with cancer the full intensity of treatment which we know gives the best chance of cure.”
Illness
Data was collected on all children with cancer in the UK who on admission to hospital tested positive for Covid-19 so that the severity of their illness could be collected nationally.
The data was shared with clinicians and the CCLG in real-time to inform advice on shielding in this group of patients. As a result, the CCLG was able to amend the shielding advice to remove the majority of children with cancer from the group needing to shield.
Lead author, Gerard Millen, Cancer Research UK Clinical Trials Fellow in the University of Birmingham’s Cancer Research UK Clinical Trials Unit said: “The Covid-19 pandemic spread rapidly in the early part of 2020 and there were initial concerns about the severity of the infection in adults with cancer. Whilst children overall seemed to be less severely affected, little was known about the effects in children with cancer.
“The results are reassuring to parents around the country that children with cancer are at no greater risk of developing serious symptoms of Covid-19 than other children.”
Vulnerable
Senior author, Professor Pam Kearns, Paediatric Oncologist and Director of the University of Birmingham Institute of Cancer and Genomic Sciences said: “This project has been critical in allowing clinicians to analyse real-time data and provide evidence to reassure families of vulnerable children and young people with cancer that they are not at increased risk of severe Covid-19 infection”.
The project was led by the University of Birmingham and involved analysis from York as well as collaboration with Public Health England, the universities of Manchester, Leeds, Nottingham, and their affiliated Children’s Hospitals.
Explore more news
New butterfly species created 200,000 years ago by two species interbreeding
Thursday 18 April 2024
Children in the North at greater risk of entering care
Wednesday 17 April 2024
Boreal forest and tundra regions worst hit over next 500 years of climate change, study shows
Monday 8 April 2024
Researchers developing ultra-sensitive blood test with potential to revolutionise diagnosis of Alzheimer’s
Thursday 4 April 2024
Attitudes to being an adult are shifting as traditional milestones become out of reach, new study finds
Wednesday 27 March 2024
Media enquiries
About this research
The paper, Severity of Covid-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project , is published in the British Journal of Cancer.
Our response to the coronavirus pandemic
We're working with partners in York and further afield as part of a global effort to fight the COVID-19 virus. From covid analysis in the labs to producing face shields for the frontline, we're using our knowledge and expertise to support the effort.